GlassScriptPhysician profile
Marisol Gandee
NPI 1700510567
$2,625.63
in general payments reported to CMS, 2019-2025
28 companies · $830 in 2025
The $830 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $330 · 2023: $910 · 2024: $556 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $374.97 | 2024-2025 | Ultomiris |
| Argenx US, INC. | $278.60 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $250.91 | 2023-2025 | |
| Lundbeck LLC | $188.07 | 2023-2025 | Vyepti |
| Pfizer INC. | $166.18 | 2023-2024 | |
| Ucb, INC. | $161.58 | 2023-2025 | Briviact |
| Axsome Therapeutics, INC. | $136.83 | 2025 | Symbravo |
| Tg Therapeutics, INC. | $125.00 | 2023 | |
| Biogen, INC. | $124.41 | 2022-2023 | Vumerity |
| Lilly USA, LLC | $101.47 | 2022-2023 | Reyvow, Emgality, Mounjaro |
| Corcept Therapeutics | $97.43 | 2024 | Korlym |
| Ani Pharmaceuticals, INC. | $71.95 | 2022 | |
| Avion Pharmaceuticals | $62.72 | 2022-2023 | Dhivy |
| Teva Pharmaceuticals USA, INC. | $58.17 | 2022-2023 | Austedo |
| Csl Behring | $52.66 | 2023 | Hizentra, Privigen |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Banner Life Sciences, LLC | $51.59 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.72 | 2024-2025 | Hyqvia |
| Biohaven Pharmaceutical Holding Company LTD. | $40.53 | 2022 | |
| Idorsia Pharmaceuticals US INC | $36.10 | 2022 | |
| Amneal Pharmaceuticals LLC | $30.62 | 2023 | Rytary |
| Horizon Therapeutics Plc | $29.24 | 2023 | Uplizna |
| Jazz Pharmaceuticals INC. | $27.17 | 2023 | |
| Emd Serono, INC. | $24.19 | 2023 | Mavenclad |
| Mannkind Corporation | $22.48 | 2024 | |
| Celgene Corporation | $22.05 | 2025 | Zeposia |
| Neurocrine Biosciences, INC. | $16.43 | 2022 | |
| Upsher-Smith Laboratories LLC | $14.61 | 2023 | |
| Sumitomo Pharma America, INC. | $9.95 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisol Gandee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.